OneSource Specialty Pharma Partners with Formycon AG to Strengthen Global Biosimilar Manufacturing

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) has announced a strategic manufacturing partnership with Formycon AG, an independent biosimilar developer headquartered in Munich, Germany, to strengthen the global production and supply of biosimilar therapies.

Announced on July 14, 2026, the collaboration will see OneSource serve as a strategic manufacturing partner for Formycon by providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing services from its state-of-the-art biologics manufacturing facility in Bengaluru.

Integrated Manufacturing for Global Biosimilar Programs

The partnership combines Formycon's expertise in biosimilar development with OneSource's end-to-end biologics manufacturing capabilities to support multiple biosimilar programs for international markets.

According to the companies, the collaboration reflects their shared commitment to expanding global access to high-quality biosimilars through reliable, scalable and cost-effective manufacturing solutions. The partnership aims to leverage scientific innovation alongside sustainable manufacturing practices to improve patient access to affordable biologic medicines worldwide.

Companies Bring Complementary Strengths

Formycon has established itself as a leading biosimilar developer with a growing commercial portfolio and a robust development pipeline. OneSource complements this with an integrated biologics platform that spans cell line development through commercial fill-finish manufacturing.

The company operates five manufacturing facilities approved by leading global regulatory authorities, including the US Food and Drug Administration (US FDA) and the European Medicines Agency (EMA), with expertise across biologics, sterile injectables and drug-device combination products.

Leadership Commentary

"We are delighted to partner with Formycon, one of the world's leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacture of world-class biologics," said Neeraj Sharma, Managing Director & CEO, OneSource Specialty Pharma.

"Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies," said Dr. Stefan Glombitza, Chief Executive Officer of Formycon AG.

Expanding Access to Affordable Biologics

The strategic alliance is expected to enhance manufacturing capacity for biosimilar products while supporting the companies' shared objective of delivering high-quality, affordable biologic therapies to patients across global markets. By combining development expertise with large-scale manufacturing capabilities, the partnership is positioned to strengthen supply chain resilience and support the growing worldwide demand for biosimilars.

(Inputs from Press Release)